Antipsychotic agents and bipolar disorder

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL. 1, 1998, Pages 38-49

  Tohen, Mauricio ^a,b   Zarate Jr , Carlos A ^a  

^a MCLEAN HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHLORPROMAZINE; CLONAZEPAM; CLOZAPINE; FLUPENTIXOL; HALOPERIDOL; LITHIUM; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; RISPERIDONE; SERTINDOLE; TIOTIXENE; VALPROATE SEMISODIUM; VALPROIC ACID;

AFFECTIVE NEUROSIS; BIPOLAR DEPRESSION; CLINICAL TRIAL; DRUG FORMULATION; DRUG MEGADOSE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAINTENANCE THERAPY; MANIA; MANIC DEPRESSIVE PSYCHOSIS; META ANALYSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; TARDIVE DYSKINESIA;

ACUTE DISEASE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; CLINICAL TRIALS; CLOZAPINE; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; HUMANS; LITHIUM; PIRENZEPINE; PSYCHOTIC DISORDERS; RISPERIDONE; TREATMENT OUTCOME;

EID: 0031885563     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (130)

1. Baldessarini RJ, Tondo L, Suppes T, et al. Pharmacological treatment of bipolar disorder across the life cycle. In: Shulman KI, Tohen M, Kutcher SP, eds. Mood Disorders Across the Life Span. New York, NY: John Wiley & Sons; 1996:299-338
2. Tohen M. Mania. In: Sederer LY, Rothschild AJ, eds. Acute Psychiatric Treatment. Baltimore, Md: Williams & Wilkins. In press
3. Zarate CA Jr, Tohen M, Banov MD, et al. Is clozapine a mood stabilizer? J Clin Psychiatry 1995;56:108-112
4. Zarate CA Jr, Tohen M, Baldessarini RJ. Clozapine in severe mood disorders. J Clin Psychiatry 1995;56:411-417
5. Tohen M, Zarate CA Jr, Centorrino F, et al. Risperidone in the treatment of mania. J Clin Psychiatry 1996;57:249-253
6. McElroy SL, Keck PE Jr, Strakowski SM. Mania, psychosis, and antipsychotics. J Clin Psychiatry 1996:57(suppl 3):14-26
7. Delay J, Deniker P, Harl J. Utilization thérapeutique psychiatrique d'une phénothiazine d'action cetrale élective (4560 RP). Ann Med Psychol 1952; 110:112-117
8. Pearlman CA. Neuroleptic malignant syndrome: a review of the literature. J Clin Psychopharmacol 1986;6:257
9. Kaplan HI, Sadock BJ. Hospitalization and the mental health service system. In: Kaplan HI, Sadock BJ, eds. Comprehensive Textbook of Psychiatry, vol 2. 5th ed. Baltimore, Md: Williams & Wilkins; 1989:2083-2089
10. Hegarty JD, Baldessarini RJ, Tohen M, et al. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994; 151:1409-1416
11. Kendell RE, Pichot P, Von Cranach M. Diagnostic criteria of English, French, German psychiatrists. Psychol Med 1974;4:187-195
12. Cooper JE, Kendell RE, Gurland BJ, et al. Psychiatric Diagnosis in New York and London: A Comparative Study of Mental Admissions. Maudsley Monograph No. 20. London, England: Oxford University Press; 1968
13. Regier DA, Myers JK, Kramer M, et al. The NIMH Epidemiologic Catchment Area (ECA) program: historical context, major objectives, and study population characteristics. Arch Gen Psychiatry 1984;41:934-941
14. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994;51:8-19
15. Tohen M, Goodwin FK. Epidemiology of bipolar disorder. Tsuang MT, Tohen M, Zahner GW, eds. In: Textbook of Psychiatric Epidemiology. New York, NY: John Wiley & Sons; 1995
16. Stoll AL, Tohen M, Baldessarini RJ, et al. Shifts in diagnostic frequencies of schizophrenia and major affective disorders at six North American psychiatric hospitals, 1972-1988. Am J Psychiatry 1993;150:1668-1673
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1990
18. Goodwin FK, Jamison KR. Manic-Depressive Illness. New York, NY: Oxford University Press, 1990
19. Chou JCY. Recent advances in treatment of acute mania. J Clin Psychopharmacol 1991;11:3-21
20. Post RM. Mood disorders: acute mania. In: Dunner, DL, ed. Current Psychiatric Therapy. Philadelphia, Pa.: WB Saunders; 1993:204-210
21. Johnson G, Gershon S, Hekiman LJ. Controlled evaluation of lithium and chlorpromazine in the treatment of manic states: an interim report. Compr Psychiatry 1968;9:563-573
22. Johnson G, Gershon S, Burdock EI, et al. Comparative effects of lithium and chlorpromazine in the treatment of acute manic states. Br J Psychiatry 1971;119:267-276
23. Spring G, Schweid D, Gray C, et al. A double-blind comparison of lithium and chlorpromazine in the treatment of manic states. Am J Psychiatry 1970;126:1306-1310
24. Takahashi R, Sakuma A, Itoh K, et al. Comparison of efficacy of lithium carbonate and chlorpromazine in mania. Arch Gen Psychiatry 1975;32: 1310-1318
25. Shopsin B, Gershon S, Thompson H, et al. A controlled comparison of lithium carbonate, chlorpromazine, and haloperidol. Arch Gen Psychiatry 1975;32:34-42
26. Janicak PG, Newman RH, Davis JM. Advances in the treatment of mania and related disorders: a reappraisal. Psychiatric Annals 1992;22:92-103
27. Prien RF, Point P, Caffey E, et al. Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Arch Gen Psychiatry 1972; 26:146-153
28. Goodwin FK, Zis AP. Lithium in the treatment of mania: comparisons with neuroleptics. Arch Gen Psychiatry 1979;36:840-844
29. Garfinkle PE, Stancer HG, Persad E. A comparison of haloperidol, lithium carbonate and their combination in the treatment of mania. J Affect Disord 1980;2:279-288
30. Delva NJ, Letemendia FJ. Lithium treatment in schizophrenia and schizoaffective disorders. Br J Psychiatry 1982;141:387-400
31. Cohen WJ, Cohen NH. Lithium carbonate, haloperidol and irreversible brain damage. JAMA 1974;230:1283-1287
32. Addonizio G. Rapid induction of extrapyramidal side effects with combined use of lithium and neuroleptics. J Clin Psychopharmacol 1985;5: 296-298
33. Biederman J, Lerner Y, Belmaker RH. Combination of lithium carbonate and haloperidol in schizoaffective disorder: a controlled study. Arch Gen Psychiatry 1979;36:327-333
34. Small JG, Kellams JJ, Milstein V, et al. A placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients. Am J Psychiatry 1975;132:1315-1317
35. Carman JS, Bigelow LB, Wyatt RJ. Lithium combined with neuroleptics in chronic schizophrenic and schizoaffective patients. J Clin Psychiatry 1981; 42:124-128
36. Janicak PG, Bresnahan DB, Sharma RP, et al. A comparison of thiothixene with chlorpromazine in the treatment of mania. J Clin Psychopharmacol 1988;8:33-37
37. Cookson J, Silverstone T, Wells B. Double-blind comparative clinical trial of pimozide and chlorpromazine in mania. Acta Psychiatr Scand 1981;64: 381-397
38. Zarate CA Jr, Tohen M. An algorithm for the treatment of first-episode psychosis. Presented at the 148th Annual Meeting of the American Psychiatric Association, May 22, 1995, Miami, Fla
39. Tohen M, Zarate CA Jr, Zarate SB, et al. The McLean/Harvard first-episode mania project: pharmacological treatment and outcome. Psychiatric Annals 1996;26(suppl):5444-5448
40. Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988;45:79-91
41. Zarate CA Jr, Daniel DG, Kinon BJ, et al. Algorithms for the treatment of schizophrenia. Psychopharmacol Bull 1995;31:461-467
42. Rifkin A, Doddi S, Karajgi B, et al. Dosage of haloperidol for mania. Br J Psychiatry 1994;165:113-116
43. Gerner RH, Stanton A. Algorithm for patient management of acute manic states: lithium, valproate, or carbamazepine? J Clin Psychopharmacol 1992;12:57-63
44. Sernyak MJ, Griffin RA, Johnson RM, et al. Neuroleptic exposure following inpatient treatment of acute mania with lithium and neuroleptic. Am J Psychiatry 1994;151:133-135
45. Baldessarini RJ, Kando JC, Centorrino F. Hospital use of antipsychotic agents in 1989 and 1993: stable dosing with decreased length of stay. Am J Psychiatry 1995;152:1038-1044
46. McEvoy JP, Hogarty G, Steingard S. Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 1991;48:739-745
47. Mukherjee S, Rosen AM, Caracci G, et al. Persistent tardive dyskinesia in bipolar patients. Arch Gen Psychiatry 1986;43:342-346
48. Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 1982;39:473-481
49. Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors. Arch Gen Psychiatry 1982;39:473-481
50. Kane JM. The role of neuroleptics in manic-depressive illness. J Clin Psychiatry 1988;49(11, suppl):12-13
51. Nasarallah HA, Churchill CM, Hamdan-Allan GA. Higher frequency of neuroleptic-induced dystonia in mania than in schizophrenia. Am J Psychiatry 1988;145:1455-1456
52. Spina E, Sturiale V, Valvo S, et al. Prevalence of acute dystonic reactions associated with neuroleptic treatment with and without anticholinergic prophylaxis. Int Clin Psychopharmacol 1993;8:21-24
53. Garza-Treviño ES, Hollister LE, Overall JE, et al. Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. Am J Psychiatry 1989;146:1598-1601
54. Santos AB, Morton WA. Use of benzodiazepines to improve management of manic agitation. Hosp Community Psychiatry 1989;40:1069-1071
55. Lenox RH, Newhouse PA, Creelman WL, et al. Adjunctive treatment of manic agitation with lorazepam versus haloperidol: a double-blind study. J Clin Psychiatry 1992;53:47-52
56. McElroy SL, Keck PE Jr, Stanton SP, et al. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatry 1996;57:142-146
57. Hirschfeld RMA, Clayton PJ, Cohen I, et al. Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry 1994;151(1, suppl):1-36
58. Suppes T, Calabrese JR, Mitchell PB, et al. Algorithms for the treatment of bipolar, manic-depressive illness. Psychopharmacol Bull 1995;31:469-474
59. Gelenberg AJ. Neuroleptics for bipolar maintenance. Biological Therapies in Psychiatry 1994;17:46-47
60. Schou M. Lithium prophylaxis: myths and realities. Am J Psychiatry 1989;146:573-576
61. Kukopulos A, Reginaldi D, Laddomada P, et al. Course of the manic-depressive cycle and changes caused by treatment. Pharmakopsychiatrie-Neuropsychopharakol 1980;13:156-167
62. McKeon P, Manley P, Swanwick G. Manic-depressive illness, II: treatment outcome in bipolar disorder subtypes. J Psychol Med 1992;9:9-12
63. Wegner JT, Catalano F, Gilbralter J, et al. Schizophrenics with tardive dyskinesia. Arch Gen Psychiatry 1985;42:860-865
64. Tohen M, Waternaux CM, Tsuang MT. Outcome in mania: a 4-year prospective follow-up of 75 patients utilizing survival analysis. Arch Gen Psychiatry 1990;47:1106-1111
65. Sernyak MJ, Woods SW. Chronic neuroleptic use in manic-depressive illness. Psychopharmacol Bull 1993;29:375-379
66. Yassa R, Ghadirian AM, Schwartz G. Prevalence of tardive dyskinesia in affective disorder patients. J Clin Psychiatry 1983;44:410-412
67. Waddington JL, Youssef HA. Tardive dyskinesia in bipolar affective disorder: aging, cognitive dysfunction, course of illness, and exposure to neuroleptics and lithium. Am J Psychiatry 1988;145:613-616
68. Dinan TG, Kohen D. Tardive dyskinesia in bipolar affective disorder: relationship to lithium therapy. Br J Psychiatry 1989;155:55-57
69. Waddington JL, Brown K, O'Neill JO, et al. Cognitive impairment, clinical course and treatment history in outpatients with bipolar affective disorder: relationship to tardive dyskinesia. Psychol Med 1989;19:897-902
70. Hunt N, Silverstone T. Tardive dyskinesia in bipolar affective disorder: a catchment area study. Int Clin Psychopharmacol 1991;6:45-50
71. Sachs GS. Use of clonazepam for bipolar affective disorder. J Clin Psychiatry 1990;51(5, suppl):31-34
72. Licht RW, Gouliaev G, Vestergaard P, et al. Treatment of manic episodes in Scandinavia: the use of neuroleptic drugs in clinical routine setting. J Affect Dis 1994;32:179-185
73. Keck PE Jr, McElroy SL, Strakowski SM, et al. Factors associated with maintenance antipsychotic treatment of patients with bipolar disorder. J Clin Psychiatry 1996;57:147-151
74. Janicak PG, Davis JM, Preskorn SH, et al. Treatment with Antipsychotics. Principles and Practice of Psychopharmacotherapy. Baltimore, Md.: Williams & Wilkins; 1993:93-184
75. White E, Cheung P, Silverstone T. Depot antipsychotics in bipolar affective disorder. Int Clin Psychopharmacol 1993;8:119-122
76. Naylor GJ, Scott CR. Depot injections for affective disorders. Br J Psychiatry 1980;136:105-108
77. Lowe MR, Batchelor DH. Depot neuroleptics and manic-depressive psychosis. Int Clin Psychopharmacol 1986;1(suppl 1):53-62
78. Lowe MR, Batchelor DH. Lithium and neuroleptics in the management of manic depressive psychosis. Human Psychopharmacology 1990;5: 267-274
79. Margakis VP. Depot injections for affective disorders. Br J Psychiatry 1980;136:408
80. Kielholz P, Terzani S, Poldinger W. The long-term treatment of periodical and cyclic depressions with flupenthixol decanoate. Int Pharmacopsychiatry 1979;14:305-309
81. Ahlfors UG, Baastrup C, Dencker SJ, et al. Flupenthixol decanoate in recurrent manic-depressive illness. Acta Psychiatr Scand 1981;64:226-237
82. Esparon J, Kolloori J, Naylor GJ, et al. Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients. Br J Psychiatry 1986;148:723-725
83. Sonne LM. Behandling af depressive tilstande med flupenthixol. Nordisk Psychiatrisk Tiddskrift 1966;20:322-324
84. Reiter P. On flupenthixol, an antidepressant of a new chemical group. Br J Psychiatry 1969;115:1399-1402
85. Parker G, Roy K, Hadzi-Pavlovic D, et al. Psychotic (delusional) depression: a meta-analysis of physical treatments. J Affect Disord 1992;24: 17-24
86. Spiker DG, Weiss JC, Dealy RS, et al. The pharmacological treatment of delusional depression. Am J Psychiatry 1985;142:430-436
87. Hendrick V, Altshuler LL, Szuba MP. Is there a role for neuroleptics in bipolar depression? J Clin Psychiatry 1994;55:533-535
88. McElroy SL, Keck PE Jr, Pope HG Jr, et al. Valproate in the treatment of rapid-cycling bipolar disorder. J Clin Psychopharmacol 1988;8:275-279
89. McElroy SL, Keck PE Jr, Pope HG Jr, et al. Clinical and research implications of the diagnosis of dysphoric or mixed mania or hypomania. Am J Psychiatry 1992;149:1633-1644
90. Calabrese JR, Delucchi GA. Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Am J Psychiatry 1990;147: 431-434
91. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994;271: 918-924
92. McElroy SL, Dessain EC, Pope GH Jr, et al. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry 1991;52:411-414
93. Banov MD, Zarate CA Jr, Tohen M, et al. Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. J Clin Psychiatry 1994;55:295-300
94. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835
95. Hillert A, Maier W, Wetzel H, et al. Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome: a functional approach. Pharmacopsychiatry 1992;25:213-217
96. Ghaemi SN, Sachs GS, Baldassano CF, et al. Management of bipolar disorder with adjunctive risperidone: response to open treatment. In: New Research Program and Abstracts of the 148th Annual Meeting of the American Psychiatric Association; May 22, 1995; Miami, Fla. Abstract NR82:77
97. Goodnick PJ. Risperidone treatment of refractory acute mania [letter]. J Clin Psychiatry 1995;56:431-432
98. Dwight MM, Keck PE Jr, Stanton SP, et al. Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder. Lancet 1994;344:554-555
99. Keck PE Jr, Wilson DR, Strakowski SM, et al. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. J Clin Psychiatry 1995;56:466-470
100. Jacobsen FM. Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J Clin Psychiatry 1995;56:423-429
101. Singh AN, Catalan J. Risperidone in HIV-related manic psychosis. Lancet 1994;344:1029-1030
102. Gilmer WS, Ferrando SJ, Goldman JD. Risperidone in the treatment of psychiatric symptoms in patients with AIDS. In: New Research Program and Abstracts of the 148th Annual Meeting of the American Psychiatric Association; May 22, 1995; Miami, Fla. Abstract NR407:165
103. Sajatovic M. A pilot study evaluating the efficacy of risperidone in treatment-refractory, acute bipolar and schizoaffective mania. Presented at the 35th annual meeting of the New Clinical Drug Evaluation Unit; May 31-June 3, 1995; Orlando, Fla. Abstract 19
104. O'Croinin F, Zibin T, Holt L. Hypomania associated with risperidone [letter]. Can J Psychiatry 1995;40:51
105. Diaz SF. Mania associated with risperidone use [letter]. J Clin Psychiatry 1996;57:41-42
106. Koek RJ, Kessler CC. Probable induction of mania by risperidone [letter]. J Clin Psychiatry 1996;57:174-175
107. Tomilson WC. Risperidone and mania. Am J Psychiatry 1996;153: 132-133
108. Kane J, Honingfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796
109. Baldessarini RJ, Frankenburg FR. Clozapine: a novel antipsychotic agent. N Engl J Med 1991;325:746-754
110. Calabrese JR, Kimmel SE, Woyshville MJ, et al. Clozapine for treatment-refractory mania. Am J Psychiatry 1996;153:759-764
111. Leppig M, Bosch B, Naber D, et al. Clozapine in the treatment of 121 outpatients. Psychopharmacology 1989;99:S77-S79
112. Battegay R, Cotar B, Fleischhauer J, et al. Results and side effects of treatment with clozapine (Leponex R). Compr Psychiatry 1977;18: 423-428
113. Suppes T, McElroy S, Gilbert J, et al. Clozapine in the treatment of dysphoric mania. Biol Psychiatry 1992;32:270-280
114. Suppes T, Rush AJ, Webb A, et al. One year randomized trial of clozapine vs. usual care in bipolar I patients. Biol Psychiatry 1996;39:531
115. Lundquist G. Prognosis and course in manic-depressive psychoses: a follow-up study of 319 first admissions. Acta Psychiatrica et Neurologica Scandinavica 1945;35(1 suppl):1-96
116. Winokur G. The Iowa 500: heterogeneity and course in manic-depressive illness (bipolar). Compr Psychiatry 1975;16:125-131
117. Dion GL, Tohen M, Anthony WA, et al. Symptoms and functioning of patients with bipolar disorder six months after hospitalization. Hosp Community Psychiatry 1988;39:652-657
118. Goldberg JF, Harrow M, Grossman LS. Course and outcome in bipolar affective disorder: a longitudinal follow-up study. Am J Psychiatry 1995; 152:379-384
119. Zarate CA Jr, Tohen M. Outcome of mania in adults. In: Shulman KI, Tohen M, Kutcher SP, eds. Mood Disorders Across the Life Span. New York, NY: John Wiley & Sons; 1996
120. Meltzer HY. Dimensions of outcome with clozapine. Br J Psychiatry 1992;160(17suppl):45-53
121. Endicott J, Spitzer RL, Fleiss JL, et al. The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976;33:766-771
122. Frankenburg FR, Zanarini MC. Uses of clozapine in nonschizophrenic patients. Harvard Rev Psychiatry 1992;2:142-150
123. Bender KJ. Advances in psychiatric medicine. New antipsychotics: concept to late-stage development. Psychiatric Times Supplement, May 1996;1-4.
124. Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol: results of the multicenter, international trial. Schizophr Res 1996;18:131
125. Beasley CM, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-123
126. Baker R, Ames D, Umbricht D, et al. Olanzapine's impact on depressive and obsessive-compulsive symptoms in schizophrenia. Psychopharmacology Bull 1995;31:549
127. Tohen M, Sanger T, Tollefson GD, et al. Olanzapine vs haloperidol in the treatment of schizoaffective bipolar patients. In: New Research Program and Abstracts of the Annual Meeting of the American Psychiatric Association; May 20, 1997; San Diego, Calif. Abstract NR206:123
128. Van Kammen DP, McEvoy JP, Targum SD, et al. A randomized controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 1996;124:168-175
129. Daniel D, Targum S, Zimbroff D, et al. Efficacy, safety, and dose response of three doses of sertindole and three doses of haloperidol in schizophrenic patients. In: Abstracts. Presented at the 34th Annual Meeting of the American College of Neuropsychopharmacology; December 10-15, 1995; San Juan, Puerto Rico
130. Hirschfeld RMA. Schizoaffective disorder and psychotic mania. Psychiatric Annals 1996;26:S435-S439